Prescription Drugs » Celebrex

Short‐term Therapy with Celecoxib and Lansoprazole Modulates Th1/ Th2 Immune Response in Human Gastric Mucosa

admin — Fri, 10 Sep 2010 07:40:19 +0000

Abstract (Source: Helicobacter) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising. Short‐term Therapy with Celecoxib and Lansoprazole Modulates Th1/ Th2 Immune Response in Human Gastric Mucosa is a post from: Prescription Drugs

Short‐term Therapy with Celecoxib and Lansoprazole Modulates Th1/ Th2 Immune Response in Human Gastric Mucosa is a post from: Prescription Drugs

Saccharomyces cerevisiae beta-Carbonic Anhydrase: Inhibition and Activation Studies.

admin — Fri, 10 Sep 2010 07:40:18 +0000

Authors: Isik S, Guler OO, Kockar F, Aydin M, Arslan O, Supuran CT
The beta-carbonic anhydrase from Saccharomyces cerevisiae (CA, EC 4.2.1.1), scCA, which is encoded by the Nce103 gene, is an effective catalyst for CO(2) hydration to bicarbonate and protons, with a k(cat) of 9.4 x 10(5) s(-1), and k(cat)/K(M) of 9.8 x 10(7) M(-1).s(-1). Its inhibition with anions and sulfonamides has been investigated, as well as its activation with amines and amino acids. Bromide, iodide and sulfamide, were the best anion inhibitors, with K(I)s of 8.7 – 10.8 microM. Benzenesulfonamides substituted in 2-, 4- and 3,4-positions with amino, alkyl, halogeno and hydroxyalkyl moieties had K(I)s in the range of 0.976 – 18.45 microM. Better inhibition (K(I)s in the range of 154 – 654 nM) was observed for benze…

Saccharomyces cerevisiae beta-Carbonic Anhydrase: Inhibition and Activation Studies. is a post from: Prescription Drugs

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

admin — Thu, 02 Sep 2010 07:41:49 +0000

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors) A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. is a post from: Prescription Drugs

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. is a post from: Prescription Drugs

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma

admin — Thu, 02 Sep 2010 07:41:49 +0000

Conclusions: : We conclude that celecoxib is a powerful tool to improve dendritic cell-based immunotherapy and is associated with a reduction in the numbers and suppressive function of MDSC. These data suggest that immunotherapy approaches benefit from simultaneously blocking cyclooxygenase-2 activity. (Source: BMC Cancer) MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma is a post from: Prescription Drugs

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma is a post from: Prescription Drugs

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.

admin — Thu, 02 Sep 2010 07:41:42 +0000

Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice

admin — Fri, 27 Aug 2010 13:00:08 +0000

Summary: The prostaglandin E2 EP1 receptor as well as the inflammatory enzyme cyclooxygenase-2 have been suggested as targets for disease modulation, improvement of therapeutic response, and restoration of pharmacosensitivity in epilepsies. Translational development of respective add-on approaches requires careful analysis of putative effects on ictogenesis.Therefore we evaluated the impact of the EP1 receptor antagonist SC-51089, the EP1 receptor agonist misoprostol and the COX-2 inhibitors celecoxib and NS-398 in the mouse amygdala kindling model of temporal lobe epilepsy.Neither celecoxib nor NS-398 affected the generation, spread and termination of seizure activity. Whereas SC-51089 did not affect the seizure threshold, the highest dose (30mg/kg) significantly decreased the seizure sev…

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Targeting the prostaglandin E2 EP1 receptor and cyclooxygenase-2 in the amygdala kindling model in mice is a post from: Prescription Drugs

Magistrate Sets Trial For Early 2012 In Drug-Related Pfizer Securities Litigation

admin — Fri, 27 Aug 2010 13:00:07 +0000

NEW YORK – Trial is set for early 2012 in securities litigation stemming from Pfizer Inc.’s marketing of painkillers Bextra and celebrex, according to the pretrial schedule set in an Aug. 20 order by a U.S. magistrate judge in New York (In re Pfizer Inc. Securities Litigation, MDL No. 1688, No. 04-9866, S.D. N.Y.). Full story on lexis.com (Source: LexisNexis® Mealey’s™ Arthritis Drugs Legal News) Magistrate Sets Trial For Early 2012 In Drug-Related Pfizer Securities Litigation is a post from: Prescription Drugs

Magistrate Sets Trial For Early 2012 In Drug-Related Pfizer Securities Litigation is a post from: Prescription Drugs

cPLA2 Is Protective Against COX Inhibitor-Induced Intestinal Damage

admin — Fri, 20 Aug 2010 09:20:11 +0000

Cytosolic phospholipase A2 (cPLA2) is the rate-limiting enzyme responsible for the generation of prostaglandins (PGs), which are bioactive lipids that play critical roles in maintaining gastrointestinal (GI) homeostasis. There has been a long-standing association between administration of cyclooxygenase (COX) inhibitors and GI toxicity. GI injury is thought to be induced by suppressed production of GI-protective PGs as well as direct injury to enterocytes. The present study sought to determine how pan-suppression of PG production via a genetic deletion of cPLA2 impacts the susceptibility to COX inhibitor–induced GI injury. A panel of COX inhibitors including celecoxib, rofecoxib, sulindac, and aspirin were administered via diet to cPLA2– / – and cPLA2+ / + littermates. Ad…

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

cPLA2 Is Protective Against COX Inhibitor-Induced Intestinal Damage is a post from: Prescription Drugs

IL-17A stimulates the expression of inflammatory cytokines via celecoxib-blocked prostaglandin in MC3T3-E1 cells

admin — Sun, 15 Aug 2010 07:40:06 +0000

Conclusion: These results suggest that IL-17A stimulates the expression of bone resorption-related inflammatory cytokines through an autocrine mechanism involving celecoxib-blocked PGs, mainly PGE2, in osteoblasts. (Source: Archives of Oral Biology) IL-17A stimulates the expression of inflammatory cytokines via celecoxib-blocked prostaglandin in MC3T3-E1 cells is a post from: Prescription Drugs

IL-17A stimulates the expression of inflammatory cytokines via celecoxib-blocked prostaglandin in MC3T3-E1 cells is a post from: Prescription Drugs

Application of a Biphasic Test for Characterization of In Vitro Drug Release of Immediate Release Formulations of Celecoxib and Its Relevance to In Vivo Absorption

admin — Sun, 15 Aug 2010 07:40:06 +0000

Molecular Pharmaceutics, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Molecular Pharmaceutics) Application of a Biphasic Test for Characterization of In Vitro Drug Release of Immediate Release Formulations of Celecoxib and Its Relevance to In Vivo Absorption is a post from: Prescription Drugs

Application of a Biphasic Test for Characterization of In Vitro Drug Release of Immediate Release Formulations of Celecoxib and Its Relevance to In Vivo Absorption is a post from: Prescription Drugs